Brück Patrick, Vilches Cisneros Natalia, Ramos López Elizabeth, Barboza Quintana Oralia, Ancer Rodríguez Jesús, Flores Gutiérrez Juan Pablo
Centro de Medicina Interna, Hematología y Oncología, Hospital Universitario Johann Wolfgang Goethe, Universidad de Frankfurt am Main, Frankfurt, Alemania.
Ginecol Obstet Mex. 2006 Oct;74(10):516-22.
Breast cancer is a general health problem that annually produces 400,000 deaths worldwide. Its early diagnosis leads to high cure rates; nevertheless, in Mexico City this happens rarely. Her2-Neu is an oncogene that is expressed on breast cancer cells, with aggressive behaviour and metastasis. In the United States 20 to 30% of the patients present an over-expression of this protein. This phenomenon has been used as a prognostic parameter and as a predictive and indication factor for therapy with monoclonal antibodies directed against this protein and for therapy with taxanes.
To know the biology and distribution of Her2-Neu expression in Mexican breast cancer patients in order to evaluate its potential as a prognostic and predictive factor in the treatment of the breast cancer.
In the cases of invasive ductal adenocarcinomas of the breast we compared by immunohistochemistry the Her2-Neu and estrogen receptor expressions with the histopathological characteristics. The results were evaluated statistically.
We found 122 cases of breast adenocarcinoma, from which we evaluated 108 for fulfilling the selection criteria of invasive ductal adenocarcinoma. Patient's mean age was 51.8 +/- 13.2 years. The mean tumour diameter was 3.5 +/- 2.0 cm and the mean number of lymph nodes with metastasis was 6.8. The Her2-Neu (score 2+ and 3+) expression was found in 36.1% of the patients. The tumour diameter and the presence of metastatic disease had strong relation with the Her2-Neu expression level. We did not find correlation with the differentiation level, the patient's age and the presence or absence of oestrogen receptors.
Since the percentage of patients with Her2-Neu expression is high (36.1%) and there is a close relation between Her2-Neu expression, the tumour size and the presence of lymph node methastasis, the determination of the oncoprotein expression could allow a more detailed prognosis and the treatment with immunotherapy and anthracyclines in order to influence the course of the breast cancer cases.
乳腺癌是一个全球性的健康问题，每年在全球导致40万人死亡。其早期诊断可带来高治愈率；然而，在墨西哥城，早期诊断的情况很少见。Her2-Neu是一种在乳腺癌细胞中表达的癌基因，具有侵袭性和转移性。在美国，20%至30%的患者存在该蛋白的过度表达。这一现象已被用作预后参数以及针对该蛋白的单克隆抗体治疗和紫杉烷类治疗的预测及指示因子。
了解Her2-Neu在墨西哥乳腺癌患者中的生物学特性和表达分布，以评估其作为乳腺癌治疗中预后和预测因子的潜力。
对于乳腺浸润性导管腺癌病例，我们通过免疫组织化学比较了Her2-Neu和雌激素受体的表达与组织病理学特征。对结果进行统计学评估。
我们发现了122例乳腺腺癌病例，其中108例符合浸润性导管腺癌的选择标准并进行了评估。患者的平均年龄为51.8±13.2岁。肿瘤平均直径为3.5±2.0厘米，有转移的淋巴结平均数量为6.8个。36.1%的患者检测到Her2-Neu（评分2+和3+）表达。肿瘤直径和转移疾病的存在与Her2-Neu表达水平密切相关。我们未发现其与分化程度、患者年龄以及雌激素受体的有无存在相关性。
鉴于Her2-Neu表达患者的比例较高（36.1%），且Her2-Neu表达、肿瘤大小和淋巴结转移之间存在密切关系，确定癌蛋白表达可为预后提供更详细的信息，并有助于采用免疫疗法和蒽环类药物治疗，从而影响乳腺癌病例的病程。
Zotero 插件